Evidence map›Paper›PMID 41268611›Full record

ArticleOncology reports2026

Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic response to the cytotoxic threat.

Hellen Röttgen, Lana Theurer, Teresa Peccerella, Ketaki Sandu, Johanna Weiss, Jürgen Burhenne, John P Neoptolemos, Beate Köberle, Dirk Theile

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hellen Röttgen *Internal Medicine IX‑Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg University Hospital, D‑69120 Heidelberg, Germany.
Lana Theurer *Department of Food Chemistry and Toxicology, Karlsruhe Institute of Technology, D‑76131 Karlsruhe, Germany.
Teresa PeccerellaDepartment of General, Visceral, and Transplantation Surgery, Heidelberg University, Medical Faculty Heidelberg, Heidelberg University Hospital, D‑69120 Heidelberg, Germany.
Ketaki SanduInternal Medicine IX‑Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg University Hospital, D‑69120 Heidelberg, Germany.
Johanna WeissInternal Medicine IX‑Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg University Hospital, D‑69120 Heidelberg, Germany.
Jürgen BurhenneInternal Medicine IX‑Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg University Hospital, D‑69120 Heidelberg, Germany.
John P NeoptolemosDepartment of General, Visceral, and Transplantation Surgery, Heidelberg University, Medical Faculty Heidelberg, Heidelberg University Hospital, D‑69120 Heidelberg, Germany.
Beate KöberleDepartment of Food Chemistry and Toxicology, Karlsruhe Institute of Technology, D‑76131 Karlsruhe, Germany.
Dirk TheileInternal Medicine IX‑Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg University Hospital, D‑69120 Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) resistance to oxaliplatin is associated with diminished drug uptake and a poor molecular apoptotic response; however, the relative contribution of each of these modes of resistance remains unclear. Accordingly, PDAC cell lines (AsPC‑1 and BxPC‑3) and human patient‑derived organoids (hPDOs; h08 and h19) were assessed in the present study, with proliferation assays, atomic absorption spectroscopy‑based quantification of intracellular oxaliplatin, luminogenic caspase 3/7 assays, PCR array‑based transcriptomic analysis and RNA sequencing performed to scrutinize the oxaliplatin resistance phenotype. Notably, AsPC‑1 cells [half maximal inhibitory concentration (IC

Indexed as

Antineoplastic AgentsCarcinoma, Pancreatic DuctalDrug Resistance, NeoplasmOxaliplatinPancreatic NeoplasmsApoptosisCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleOrganoidsAntineoplastic AgentsOxaliplatinAsPC‑1BxPC‑3drug uptakehuman patient‑derived organoidsoxaliplatin resistancepancreatic ductal adenocarcinoma

Identifiers

PMID41268611
PMCPMC12670068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.